欣百达

每周平均疼痛分数上欣百达胜过安慰剂的那项研究中，使用了60mg欣百达、120mg欣百达和安慰剂。

The study in which Cymbalta bested the placebo for average weekly pain scores used a60 milligram dose of Cymbalta , a120 milligram dose , or a placebo .

而那项欣百达未能打败安慰剂的研究中，包含更低的20mg欣百达剂量组，以及60mg欣百达、120mg欣百达和安慰剂。

The study in which Cymbalta didn 't beat the placebo also included a lower ( 20 milligram ) dose of Cymbalta , as well as the60 milligram dose , 120 milligram dose , and placebo .

从第三周到第十一周，欣百达的效果胜过安慰剂，但在整个研究总体上没有胜出。

Cymbalta trumped the placebo from the third to the eleventh weeks , but not for the entire study overall .

在服用欣百达或者安慰剂之前，测量每周疼痛指数的平均值，并在研究结束时再次测量。结果表明服用欣百达的一组患者有更明显的改善。

Average weekly pain scores , measured before taking Cymbalta or the placebo and again at the end of the study , showed greater improvement in the Cymbalta group .

在两项研究中，患者服用欣百达后，报告的常见副作用包括恶心、口干、疲劳、腹泻、过量出汗（多汗症）、头晕和便秘。

In both studies , side effects more commonly reported by patients taking Cymbalta included nausea , dry mouth , fatigue , diarrhea , excessive sweating ( hyperhidrosis ), dizziness , and constipation .

在这次的研究中，患有慢性腰部疼痛的成年人在连续13周每日服用一次欣百达或者安慰剂后，两组患者的每周平均疼痛程度与服药之前相比，之间的变化没有显著差异。

In that study , there weren 't any significant differences in before-and-after average weekly pain ratings among adults with chronic low back pain who took Cymbalta or a placebo once daily for13 weeks .